Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2026 08:14 ET | Source: Robbins Geller Rudman & Dowd LLP

Soleno Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action filed by Robbins Geller Rudman & Dowd LLP

The Soleno complaint alleges that Soleno Phase 3 clinical trial program for DCCR had downplayed, misrepresented, and/or concealed safety concerns.
March 25, 2026 08:23 ET | Source: Grabar Law Office

Important Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Integer Holdings Corp. (NYSE: ITGR); Molina Healthcare, Inc. (NYSE: MOH); and Soleno Therapeutics, Inc. (NASDAQ: SLNO): Grabar Law Office Investigates Claims on Your Behalf

Stock Investigations: ASP Isotopes (NASDAQ: ASPI); Integer Holdings (NYSE: ITGR); Molina Healthcare (NYSE: MOH); and Soleno Therapeutics (NASDAQ: SLNO)
March 23, 2026 08:54 ET | Source: Grabar Law Office

Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Integer Holdings Corp. (NYSE: ITGR); Molina Healthcare, Inc. (NYSE: MOH); and Soleno Therapeutics, Inc. (NASDAQ: SLNO): Grabar Law Office Investigates Claims on Your Behalf

ASP Isotopes Inc. (NASDAQ: ASPI); Integer Holdings Corp. (NYSE: ITGR); Molina Healthcare, Inc. (NYSE: MOH); and Soleno Therapeutics, Inc. (NASDAQ: SLNO)
March 22, 2026 14:45 ET | Source: Robbins Geller Rudman & Dowd LLP

INVESTOR DEADLINE: Soleno Therapeutics Inc. (SLNO) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law

The Soleno complaint alleges that Soleno Phase 3 clinical trial program for DCCR had downplayed, misrepresented, and/or concealed safety concerns.
March 20, 2026 09:41 ET | Source: Grabar Law Office

Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Integer Holdings Corp. (NYSE: ITGR); Molina Healthcare, Inc. (NYSE: MOH); and Soleno Therapeutics, Inc. (NASDAQ: SLNO): Grabar Law Office Investigates Claims on Your Behalf

Attention Shareholders of ASP Isotopes (NASDAQ: ASPI); Integer Holdings (NYSE: ITGR); Molina Healthcare (NYSE: MOH); and Soleno Therapeutics (NASDAQ: SLNO)
March 18, 2026 14:45 ET | Source: Robbins Geller Rudman & Dowd LLP

INVESTOR DEADLINE: Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law

The Soleno complaint alleges that Soleno Phase 3 clinical trial program for DCCR had downplayed, misrepresented, and/or concealed safety concerns.
March 18, 2026 09:17 ET | Source: Grabar Law Office

Important Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Integer Holdings Corp. (NYSE: ITGR): Soleno Therapeutics, Inc. (NASDAQ: SLNO); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office is Investigating Claims on Your Behalf

ASP Isotopes (NASDAQ: ASPI); Integer Holdings (NYSE: ITGR): Soleno Therapeutics (NASDAQ: SLNO); and Unicycive (NASDAQ: UNCY) Shareholder Notice
March 16, 2026 09:31 ET | Source: Grabar Law Office

Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Camping World Holdings, Inc. (NYSE: CWH); Soleno Therapeutics, Inc. (NASDAQ: SLNO); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf

ATTN Shareholders of ASP Isotopes (NASDAQ: ASPI); Camping World Holdings (NYSE: CWH); Soleno Therapeutics (NASDAQ: SLNO); and Unicycive (NASDAQ: UNCY)
March 14, 2026 12:29 ET | Source: Grabar Law Office

Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Camping World Holdings, Inc. (NYSE: CWH); EOS Energy Enterprise, Inc. (NASDAQ: EOSE); and Soleno Therapeutics, Inc. (NASDAQ: SLNO): Grabar Law Office Investigates Claims on Your Behalf

Notice to Long-Term Shareholders of ASP Isotopes (NASDAQ: ASPI); Camping World (NYSE: CWH); EOS Energy (NASDAQ: EOSE); and Soleno (NASDAQ: SLNO)
March 11, 2026 16:10 ET | Source: Robbins Geller Rudman & Dowd LLP

INVESTOR NOTICE: Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law

The Soleno complaint alleges that Soleno Phase 3 clinical trial program for DCCR had downplayed, misrepresented, and/or concealed safety concerns.